Article citationsMore >>

Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER, Castellano D, Choueiri TK,Gurney H, Donskov F, Bono P, Wagstaff J, Gauler TC, Ueda T, Tomita Y, Schutz FA, Kollmannsberger C, Larkin J, Ravaud A, Simon JS, Xu LA, Waxman IM, Sharma P; CheckMate 025 Investigators. Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med. 2015 Nov 5; 373(19): 1803-13.

has been cited by the following article:

Article

Severe Pneumonitis in Patient with Kidney Cancer Using Nivolumab after Influenza Vaccine - A Case Report

1Medical oncologist at the Hospital City of Passo Fundo- RS- BR. Street Tiradentes

2Medical resident in Oncology at the Hospital City of Passo Fundo


American Journal of Medical Case Reports. 2017, Vol. 5 No. 6, 151-155
DOI: 10.12691/ajmcr-5-6-5
Copyright © 2017 Science and Education Publishing

Cite this paper:
Nicoli Taiana Henn, Julia Pastorello, Marina Ractz Bueno. Severe Pneumonitis in Patient with Kidney Cancer Using Nivolumab after Influenza Vaccine - A Case Report. American Journal of Medical Case Reports. 2017; 5(6):151-155. doi: 10.12691/ajmcr-5-6-5.

Correspondence to: Nicoli  Taiana Henn, Medical oncologist at the Hospital City of Passo Fundo- RS- BR. Street Tiradentes. Email: nicolihenn@yahoo.com.br

Abstract

Immunotherapies are new drugs that are revolutionizing the treatment of many malignancies, among them, the kidney cancer. Because of their mechanism of action they can trigger an important inflammatory responses and immune-mediated adverse events. The safety of influenza vaccination during the use of checkpoint inhibitors is not defined. We report the case of a patient with kidney cancer who evolved unfavorably a few days after receiving the influenza immunization without the consent of the oncology specialists.

Keywords